Navigation Links
The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone
Date:3/23/2010

IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough and is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20%. Patients diagnosed with IPF are usually between the ages of 40 and 70, with a median age of 63 years and the disease tends to affect slightly more men than women. There are no medicines approved in Europe and the United States for the treatment of IPF.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY) and a New Drug Application (NDA) has been accepted for Priority Review by the FDA and a Marketing Authorization Application (MAA) is under review by the European Medicines Agency (EMA). The hepatology portfolio includes the HCV protease inhibitor compound RG7227 (formerly ITMN-191) that entered Phas
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Promega Maxwell 16 IVD System CE Marked to the European Union IVD Directive Delivers Combined Solution for Infectious Disease
2. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
3. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
4. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
5. Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters
6. Lower detection of prostate cancer with PSA screening in US than in a European randomized trial
7. European Cancer Organization supports a revision of the EU Clinical Trials Directive
8. Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
9. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
10. The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center
11. Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... 02, 2015 , ... The 2015 China Overseas Investment and ... business conference will be hosted at five star Beijing Kunlun Hotel and Diaoyutai ... will feature leading EB-5 industry professionals and Chinese private equity partners looking for ...
(Date:9/2/2015)... ... September 02, 2015 , ... World Patent Marketing, a vertically ... safety invention that protects people from crime and other hostile situations. , "The ... CEO and Creative Director of World Patent Marketing. "The industry is growing at ...
(Date:9/2/2015)... Fredericksburg, VA (PRWEB) , ... September 02, 2015 ... ... integrator of document imaging, content, records and case management solutions and services to ... of PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... helping to bring awareness to International Overdose Awareness Day. The goal is to ... recognize the warning signs so that they may get help. , ...
(Date:9/2/2015)... ... 02, 2015 , ... The payroll conference theme this year ... education covering legislative updates, including unemployment, global payroll best practices, and the latest ... Ultimate Software, the American Payroll Association, Barnett Associates, and the IRS, will keep ...
Breaking Medicine News(10 mins):Health News:The 2015 China Overseas Investment and Entrepreneurship Summit (COIES) Announced 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 2Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 3Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 4Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 5Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 6Health News:What Should You Be Watching As You Walk Alone At Night - World Patent Marketing's Hand Free Pocket Cop Invention 7Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:23rd Annual NJ Statewide Payroll Conference in Vernon, NJ at the Minerals Hotel on October 15-16, 2015 2
... The Generic Pharmaceutical Association (GPhA) will discuss the results ... healthcare market intelligence company, revealing that generic pharmaceutical utilization has ... system in the last decade., What: ... ...
... Suction Provides Permanent Reduction of Excessive Sweat and Smells , ... ... sweating and body odor affects 176 million people and in most ... breakthrough procedure, Hypo Lipo , ( Axillary Curettage Suction ) ...
... 7 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... quarter ended March 31, 2009. "Our focus for the ... the NDA submission for pixantrone while we implemented final ... needed operating capital on the least dilutive terms possible ...
... 20% to $0.49 per outstanding common share from ... in Q1 2008)- Improved average monthly revenue per ... occupancy was 88.7%, down from 90.0% in Q1 ... to $497.9 million- Improved Facility Operating Income by ...
... - Sanofi Pasteur committed to increasing its seasonal ... production capacity in the U.S. -SWIFTWATER, Pa. and ... vaccines division of sanofi-aventis Group (EURONEXT: SAN and ... the U.S. Food and Drug Administration (FDA) has ...
... 125,000-member Indiana American Legion today challenged the Indiana General ... plainly on behalf of the youngsters at the Indiana ... on legislators to "not use the current budget impasse ... announced by the Indiana State Department of Health, would ...
Cached Medicine News:Health News:Dr. Elliot Jacobs' New 'Hypo Lipo' Procedure Permanently Reduces Hyperhidrosis and Body Odor 2Health News:Dr. Elliot Jacobs' New 'Hypo Lipo' Procedure Permanently Reduces Hyperhidrosis and Body Odor 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 2Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 3Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 4Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 5Health News:Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009 6Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 2Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 3Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 4Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 5Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 6Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 7Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 8Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 9Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 10Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 11Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 12Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 13Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 14Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 15Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 16Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 17Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 18Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 19Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 20Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 21Health News:Brookdale Announces First Quarter 2009 Results; CFFO of $0.49 per Share 22Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 5Health News:U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility 6Health News:Legion Demands 'Courage' From Legislators in Battle Over Children's Home 2
(Date:9/2/2015)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... for cancer, today announced results for its fiscal year ... http://photos.prnewswire.com/prnh/20140805/133834 "Despite a challenging end ... how the Company is positioned entering fiscal year 2016," ... Chief Executive Officer of MEI Pharma. "While we were ...
(Date:9/2/2015)... , Sept. 2, 2015 Delcath Systems, Inc. ... device company focused on oncology with an emphasis on ... that Company management will participate in the upcoming 17 ... from September 8-10, 2015 at the St. Regis Hotel ... MSN, CRNP, Delcath,s President and Chief Executive Officer, will ...
(Date:9/2/2015)... N.J. , Sept. 2, 2015 CytoSorbents ... leader commercializing its CytoSorb ® blood purification technology ... the world, announced that CEO Dr. Phillip Chan ... Renshaw Annual Global Investment Conference (sponsored by H.C. ... th in New York City.  ...
Breaking Medicine Technology:MEI Pharma Reports Fiscal Year 2015 Results 2MEI Pharma Reports Fiscal Year 2015 Results 3MEI Pharma Reports Fiscal Year 2015 Results 4MEI Pharma Reports Fiscal Year 2015 Results 5MEI Pharma Reports Fiscal Year 2015 Results 6MEI Pharma Reports Fiscal Year 2015 Results 7Delcath To Present At The 17th Annual Rodman & Renshaw Conference 2Delcath To Present At The 17th Annual Rodman & Renshaw Conference 3CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 2CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 3CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 4
... 4 A new report identifies five Internet companies, ... that display fake pharmacy licenses or sell prescription drugs without a prescription. ... Between December ... and KnujOn provided sixteen domain name registrars with evidence ...
... ,, NEW YORK , May 4 Reportlinker.com announces that a new market research report is ... Global Pain Relieving Drug Market Analysis 2010-2025 , ... , , ... – where will opportunities lie in this diverse market with high, growing demand worldwide? ...
Cached Medicine Technology:Fake Pharmacy Licenses, No-Prescription Meds OK with Internet Companies, LegitScript Reports 2Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 2Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 3Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 4Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 5Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 6Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 7Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 8Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 9Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 10Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 11Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 12Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 13Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 14Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 15Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 16Reportlinker Adds Global Pain Relieving Drug Market Analysis 2010-2025 17
... Olympus TrueView II telescopes are based on ... unique wide field of view allows a tremendous ... view supports easy navigation in the joint with ... new quick lock mechanism for tight and secure ...
... WASCA Analyzer provides youwith new, exciting possibilities ... the WASCA Analyzeranalyzes the optical properties of ... the retina. In addition to refractive values, ... aberrations which were largely ignored in the ...
... Flow Unit is a flexible, total solution. , ... operating theaters since 1983. A major part of ... extensive experience from all the different areas of ... , ,Kojair Tech Oy is a comprehensive supplier. ...
The Universal Knee Positioner(s)™ reduces surgeon fatigue while assisting in the stabilization of a patient's leg during surgury....
Medicine Products: